Morgan Stanley cuts Novo Nordisk to Underweight
Novo Nordisk shares fell more than 2% after Morgan Stanley lowered its rating to Underweight from Equal-weight, citing longer-term semaglutide risks and potential generic competition.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.